This is the arbitrage opportunity. The pharmaceutical secondary market — distressed assets, out-licensed compounds, abandoned pipelines, post-patent small molecules — […]
Buy Old Science Cheap, Sell Proven Biology Expensive Read Post »
The instinct, when a primary patent approaches expiration, is to treat it as a loss event. Revenue projections get marked
The pharmaceutical industry operates on a high-risk model where the cost of a single drug approval ranges from $1 billion
Turn Abandoned Patents Into Profit Read Post »
Pharmaceutical manufacturers face a revenue contraction of 62% from their top-selling assets by 2030.1 Blockbuster drugs representing $236 billion in
Drug Reformulation Strategy: Buy Seven Years of Exclusivity for $20 Million Read Post »
How to use market automation and drug patent intelligence to build pipeline before generic entry kills your best customers’ budgets
Sell Before the Cliff Drops: A BD Playbook for Biopharma Equipment Suppliers Read Post »
Pharmaceutical companies lose between $200 billion and $400 billion in annual revenue to patent expirations between 2025 and 2030. This
Forecasting Generic Entry: Combining FDA Orange Book with Paragraph IV Notice Letters Read Post »
The Statute That Rewired the Drug Industry In September 1984, President Reagan signed two pieces of legislation that had been
Branded Generics: The $400 Billion Business That Big Pharma Can’t Ignore In the summer of 2022, a pharmacist in Lagos
Why Branded Generics Dominate the Pharmaceutical Landscape in Emerging Markets Read Post »
The companies winning enterprise contracts in biopharma data intelligence aren’t selling better patent databases. They’re selling a connected answer to
Get fresh news and insights, drug patent expirations & more…
